The data and insights highlighted in the article are drawn from the Biotech Playbook for Progress, a comprehensive resource built from a 2025 TriNetX survey of 150 biotech and pharma…
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1…
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered candidate, dubbed ONO-4578,…
England’s AviadoBio is looking to China as a potential source of additional gene therapies, securing an option to a $413 million biobucks deal that could deliver a clinical-stage rare eye…
Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero…
Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate Lisata’s tumor drug. At the center of the deal is…
After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to…
New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated with Alzheimer’s disease. Amongst the risks are inflammation-related factors. Researchers Look at Inflammation Biomarkers…
Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3…
In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so,…